

# ADDITION OF IMMUNE CHECKPOINT INHIBITORS TO CHEMOTHERAPY VS CHEMOTHERAPY ALONE AS FIRST-LINE TREATMENT IN EXTENSIVE STAGE SMALL-CELL LUNG CARCINOMA (ES-SCLC)

PEER-REVIEWED  
INFOGRAPHIC

OPEN  
ACCESS

## Systematic review and meta-analysis

Edurne Arriola, Maria Gonzalez Cao, Manuel Domine, Javier De Castro, Manuel Cobo, Reyes Bernabé, Alejandro Navarro, Ivana Sullivan, José Trigo, Joaquín Mosquera, Leonardo Crama, Dolores Isla.

### Key findings

Immunotherapy combined with platinum-etoposide chemotherapy from the induction phase is **superior to chemotherapy as a first-line treatment** in ES-SCLC patients



### Methods

Specific search strategies for randomized controlled trials (RCT) in the main databases



A random-effects meta-analysis and subgroups analyses



### Results

EFFICACY

SAFETY

#### Chemotherapy (CT)

Including placebo associated with the chemotherapy or chemotherapy alone



#### V S Immune checkpoint inhibitors + CT

Including different ICI agents (ipilimumab, nivolumab, pembrolizumab, atezolizumab and durvalumab) as induction and maintenance therapy

